$2.00 2.4%
CRVS Stock Price vs. AI Score (Last 150 days)
Data gathered: July 16

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.

Corvus Pharmaceuticals
Price $2.00
Target Price Sign up
Volume 167,750
Market Cap $123M
Year Range $1.33 - $2.41
Dividend Yield 0%
Revenue per Employee $8,786
Industry Biotechnology

In the news

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '2402.2M-2.2M-5.7M-6.2M-0.120
Q4 '23250,0001.7M-3.1M-6.7M-5.6M-0.140
Q3 '2301.6M-2.5M-6M-5.5M-0.120
Q2 '2301.7M-3M-6.5M-5.6M-0.140
Q1 '2302M-3.8M-7.9M-6.5M-0.170

Insider Transactions View All

Jones William Benton filed to buy 19,357 shares at $0.
May 7 '24
Jones William Benton filed to buy 153,773 shares at $1.7.
May 7 '24
MILLER RICHARD A MD filed to buy 559,073 shares at $0.
May 7 '24
MILLER RICHARD A MD filed to buy 577,634 shares at $1.7.
May 7 '24
ORBIMED ADVISORS LLC filed to buy 1,397,684 shares at $0.
May 8 '24

What is the Market Cap of Corvus Pharmaceuticals?

The Market Cap of Corvus Pharmaceuticals is $123M.

How Many People Work at Corvus Pharmaceuticals?

As of our latest update, Corvus Pharmaceuticals employed approximately 28 people worldwide. However, it's important to note that Corvus Pharmaceuticals' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Corvus Pharmaceuticals' revenue per employee?

$8,786. To calculate Corvus Pharmaceuticals' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Corvus Pharmaceuticals?

Currently, the price of one share of Corvus Pharmaceuticals stock is $2.00.

How can I analyze the CRVS stock price chart for investment decisions?

The CRVS stock price chart above provides a comprehensive visual representation of Corvus Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Corvus Pharmaceuticals shares. Our platform offers an up-to-date CRVS stock price chart, along with technical data analysis and alternative data insights.

Does CRVS offer dividends to its shareholders?

As of our latest update, Corvus Pharmaceuticals (CRVS) does not offer dividends to its shareholders. Investors interested in Corvus Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Corvus Pharmaceuticals?

Some of the similar stocks of Corvus Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.